Eli Lilly acquiring immune therapy developer Dice Therapeutics for $2.4B
Eli Lilly said this week it has inked an agreement to acquire Dice Therapeutics, a biopharma firm developing novel oral therapeutic candidates, for $2.4 billion in cash. Read More
Future Fields, Jenthera Therapeutics collaborate to develop novel protein for the delivery of cancer biologics
Biotech firm Future Fields and gene-editing firm Jenthera Therapeutics this week announced a collaboration focused on the manufacturing of a first-of-its-kind cancer-fighting protein. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
